Chinese journal of cancer research = Chung-kuo yen cheng yen chiu最新文献

{"title":"When immunotherapy meets liver transplantation for hepatocellular carcinoma: A bumpy but promising road.","authors":"Yufeng Gu,&nbsp;Shengjun Xu,&nbsp;Zhengxin Wang,&nbsp;Jiayin Yang,&nbsp;Shusen Zheng,&nbsp;Qiang Wei,&nbsp;Zhikun Liu,&nbsp;Xiao Xu","doi":"10.21147/j.issn.1000-9604.2023.02.02","DOIUrl":"10.21147/j.issn.1000-9604.2023.02.02","url":null,"abstract":"<p><p>Liver transplantation (LT) is a highly curative therapy for patients with hepatocellular carcinoma (HCC). However, due to the shortage of donor livers and rapid progression of HCC, a majority of patients are dropped out from the waitlist. Recently, immunotherapy has shown great promise in the treatment of advanced HCC. However, the use of immunotherapy is limited in LT mainly due to the potentially increasing risk of graft rejection. One of the main challenges for researchers is the protection of donor graft from an immunotherapy-boosted immune response mounted by the host. Besides, the safety, availability, and costs of immunotherapy are other challenges that need to be addressed. Here, we reviewed the literature involving patients who received immunotherapy prior to transplant to avoid waitlist dropouts and following transplantation to prevent the progression of tumor recurrence and metastasis. Statistically, the incidence of rejection was 25.0% pre-transplant and 18.5% post-transplant. Based on the review of these clinical studies, we can conclude that conducting clinical trials on the safety and efficacy of currently available immunotherapy drugs and identifying novel immunotherapy targets through extensive research may be promising for patients who do not meet the selection criteria for LT and who experience post-transplant recurrence. To date, the clinical experience on the use of immunotherapy before or after LT comes from individual case studies. Although some of the reported results are promising, they are not sufficient to support the standardized use of immunotherapy in clinical practice.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"35 2","pages":"92-107"},"PeriodicalIF":0.0,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167603/pdf/cjcr-35-2-92.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9461902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aqueous-soluble components of sporoderm-removed <i>Ganoderma lucidum</i> spore powder promote ferroptosis in oral squamous cell carcinoma.","authors":"Xiangping Wu,&nbsp;Qingnan Wu,&nbsp;Yan Wang,&nbsp;Yehai Liu,&nbsp;Zhenhao Li,&nbsp;Qingchuan Liu,&nbsp;Zhengming Huang,&nbsp;Mingyan Li,&nbsp;Bin Zhang,&nbsp;Qimin Zhan","doi":"10.21147/j.issn.1000-9604.2023.02.07","DOIUrl":"10.21147/j.issn.1000-9604.2023.02.07","url":null,"abstract":"<p><strong>Objective: </strong>Ferroptosis is a novel cell death process which displays a promising role in cancer treatment. However, clinically available drugs targeting ferroptosis are rarely used, and yet there are no studies reporting on inducing ferroptosis via Chinese herbal extracts. Here we explored the tumor inhibition effects of <i>Ganoderma lucidum</i> (<i>G. lucidum</i>) on oral squamous cell carcinoma (OSCC). Specifically, we aimed to clarify the biological mechanism of components in the dietary, aqueous-soluble sporoderm-removed <i>G. lucidum</i> spore powder (A-GSP).</p><p><strong>Methods: </strong>Preliminary transcriptome analysis revealed the significant enrichment of the ferroptosis pathway. Cellular Fe²⁺, glutathione (GSH), malondialdehyde (MDA), reactive oxygen species (ROS) and lipid peroxide levels were measured to identify ferroptosis occurrence. Western blotting was used to measure ferroptosis-related proteins. Changes in mitochondria morphology and function were observed with transmission electron microscopy (TEM) and ATP detection assays. Ferroptosis inhibitor ferrostatin-1 was then used to verify the anti-tumor effects of A-GSP. Finally, nude mice xenograft models of oral cancer confirmed that A-GSP inhibited tumor growth.</p><p><strong>Results: </strong>A-GSP promoted ferroptosis in oral cancer cells by inducing Fe²⁺ influx, GSH depletion, as well as lipid peroxide and ROS accumulation. Ferroptosis-related proteins exhibited corresponding changes, particularly Acyl-coA synthetase long chain family member 4 (ACSL4) increase and glutathione peroxidase 4 (GPX4) decrease. A-GSP considerably lowered mitochondrial volume and ridge number, while significantly decreasing ATP production. Ferrostatin-1 reversed all of these A-GSP-induced changes. <i>In vivo</i>, A-GSP exerted a ferroptosis-mediated tumor-suppressing effect without observable adverse reactions.</p><p><strong>Conclusions: </strong>Our findings demonstrate the therapeutic potential of A-GSP for treating patients with OSCC by targeting ferroptosis.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"35 2","pages":"176-190"},"PeriodicalIF":0.0,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167607/pdf/cjcr-35-2-176.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9461899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated strategies for chemotherapy cycles in nasopharyngeal carcinoma patients: Real-world data from two epidemic centers guiding decision-making.","authors":"Zejiang Zhan,&nbsp;Yingying Huang,&nbsp;Jiayu Zhou,&nbsp;Zhuochen Cai,&nbsp;Haoyang Huang,&nbsp;Ying Deng,&nbsp;Wenze Qiu,&nbsp;Xun Cao,&nbsp;Xi Chen,&nbsp;Chixiong Liang,&nbsp;Lulu Zhang,&nbsp;Xiang Guo,&nbsp;Taize Yuan,&nbsp;Xing Lyu","doi":"10.21147/j.issn.1000-9604.2023.02.04","DOIUrl":"10.21147/j.issn.1000-9604.2023.02.04","url":null,"abstract":"<p><strong>Objective: </strong>Two cycles of induction chemotherapy (IC) followed by 2 cycles of platinum-based concurrent chemoradiotherapy (CCRT) (2IC+2CCRT) for locoregionally advanced nasopharyngeal carcinoma (LA-NPC) is widely adopted but not evidence-confirmed. This study aimed to determine the clinical value of 2IC+2CCRT regarding efficacy, toxicity and cost-effectiveness.</p><p><strong>Methods: </strong>This real-world study from two epidemic centers used propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) analyses. The enrolled patients were divided into three groups based on treatment modality: Group A (2IC+2CCRT), Group B (3IC+2CCRT or 2IC+3CCRT) and Group C (3IC+3CCRT). Long-term survival, acute toxicities and cost-effectiveness were compared among the groups. We developed a prognostic model dividing the population into high- and low-risk cohorts, and survivals including overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS) and locoregional relapse-free survival (LRRFS) were compared among the three groups according to certain risk stratifications.</p><p><strong>Results: </strong>Of 4,042 patients, 1,175 were enrolled, with 660, 419, and 96 included in Groups A, B and C, respectively. Five-year survivals were similar among the three groups after PSM and confirmed by IPTW. Grade 3-4 neutropenia and leukocytopenia were significantly higher in Groups C and B than in Group A (52.1% <i>vs.</i> 41.5% <i>vs.</i> 25.2%; 41.7% <i>vs.</i> 32.7% <i>vs.</i> 25.0%) as were grade 3-4 nausea/vomiting and oral mucositis (29.2% <i>vs.</i> 15.0% <i>vs.</i> 6.1%; 32.3% <i>vs.</i> 25.3% <i>vs.</i> 18.0%). Cost-effective analysis suggested that 2IC+2CCRT was the least expensive, while the health benefits were similar to those of the other groups. Further exploration showed that 2IC+2CCRT tended to be associated with a shorter PFS in high-risk patients, while 3IC+3CCRT potentially contributed to poor PFS in low-risk individuals, mainly reflected by LRRFS.</p><p><strong>Conclusions: </strong>In LA-NPC patients, 2IC+2CCRT was the optimal choice regarding efficacy, toxicity and cost-effectiveness; however, 2IC+2CCRT and 3IC+3CCRT probably shortened LRRFS in high- and low-risk populations, respectively.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"35 2","pages":"126-139"},"PeriodicalIF":0.0,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167606/pdf/cjcr-35-2-126.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9461900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming cancer cells for long-term living with cancer: An inspiring new approach.","authors":"Mingjie Jiang,&nbsp;Dianna Gu,&nbsp;Furao Liu,&nbsp;Chenjing Lin,&nbsp;Ling Tian","doi":"10.21147/j.issn.1000-9604.2023.02.03","DOIUrl":"10.21147/j.issn.1000-9604.2023.02.03","url":null,"abstract":"<p><p>Cancer is the leading cause of human death and imposes a huge health burden. Currently, no matter what advanced therapeutic modalities or technologies are applied, it is still peculiarly rare for most cancers to be radically cured whereas therapy resistance and tumor recurrence are ever so common. The long-standing cytotoxic therapy is hard to achieve long-term tumor control, and produces side-effects or even promotes cancer progression. With growing understandings of tumor biology, we came to realize that it is possible to transform but not kill cancer cells to achieve long-term living with cancer, and directly altering cancer cells is a promising way. Remarkably, tissue microenvironment is involved in the fate determination of cancer cells. Of note, leveraging cell competition to combat malignant or therapy-resistant cells shows some therapeutic potentials. Furthermore, modulating tumor microenvironment to restore a normal state might help to transform cancer cells. Especially, reprogramming cancer-associated fibroblasts, and tumor-associated macrophages, or normalization of tumor vessel, tumor immune microenvironment, and tumor extracellular matrix or their combinations, <i>et al</i>., revealed some long-term therapeutic benefits. Despite the massive challenges ahead, it would be possible to transform cancer cells for long-term cancer control and living with cancer longevously. The related basic researches and corresponding therapeutic strategies are also ongoing.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"35 2","pages":"108-125"},"PeriodicalIF":0.0,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167610/pdf/cjcr-35-2-108.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9461904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration and optimization of surgical techniques for laparoscopic transhiatal lower mediastinal lymph node dissection for adenocarcinoma of esophagogastric junction: A prospective IDEAL 2a study with qualitative design.","authors":"Yinkui Wang,&nbsp;Fanling Hong,&nbsp;Shuangxi Li,&nbsp;Fei Shan,&nbsp;Yongning Jia,&nbsp;Rulin Miao,&nbsp;Zhemin Li,&nbsp;Ziyu Li,&nbsp;Jiafu Ji","doi":"10.21147/j.issn.1000-9604.2023.02.06","DOIUrl":"10.21147/j.issn.1000-9604.2023.02.06","url":null,"abstract":"<p><strong>Objective: </strong>To explore the change and feasibility of surgical techniques of laparoscopic transhiatal (TH)-lower mediastinal lymph node dissection (LMLND) for adenocarcinoma of the esophagogastric junction (AEG) according to Idea, Development, Exploration, Assessment, and Long-term follow-up (IDEAL) 2a standards.</p><p><strong>Methods: </strong>Patients diagnosed with AEG who underwent laparoscopic TH-LMLND were prospectively included from April 14, 2020, to March 26, 2021. Clinical and pathological information as well as surgical outcomes were quantitatively analyzed. Semistructured interviews with the surgeon after each operation were qualitatively analyzed.</p><p><strong>Results: </strong>Thirty-five patients were included. There were no cases of transition to open surgery, but three cases involved combination with transthoracic surgery. In qualitative analysis, 108 items under three main themes were detected: explosion, dissection, and reconstruction. Revised instruction was subsequently designed according to the change in surgical technique and the cognitive process behind it. Three patients had anastomotic leaks postoperatively, with one classified as Clavien-Dindo IIIa.</p><p><strong>Conclusions: </strong>The surgical technique of laparoscopic TH-LMLND is stable and feasible; further IDEAL 2b research is warranted.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"35 2","pages":"163-175"},"PeriodicalIF":0.0,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167605/pdf/cjcr-35-2-163.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9461898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mn-based cGAS-STING activation for tumor therapy.","authors":"Aiping Huang,&nbsp;Wenhu Zhou","doi":"10.21147/j.issn.1000-9604.2023.01.04","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2023.01.04","url":null,"abstract":"<p><p>Immunotherapy has efficiently revolutionized the treatment of human neoplastic diseases. However, the overall responsive rate of current immunotherapy is still unsatisfactory, benefiting only a small proportion of patients. Therefore, significant attention has been paid to the modulation of tumor microenvironment (TME) for the enhancement of immunotherapy. Interestingly, recent studies have shown that cyclic GMP-AMP synthase-stimulator of interferon gene (cGAS-STING) was initially found as an innate immune sensor to recognize cytoplasmic DNA (such as bacterial, viral, micronuclei, and mitochondrial). It is a promising signaling pathway to activate antitumor immune responses via type I interferon production. Notably, Mn²⁺ was found to be a critical molecule to sensitize the activation of the cGAS-STING pathway for better immunotherapy. This activation led to the development of Mn²⁺-based strategies for tumor immunotherapy via the activation of the cGAS-STING pathway. In this critical review, we aimed to summarize the recent progress of this field, focusing on the following three aspects. First, we briefly introduced the signaling pathway of cGAS-STING activation, and its regulation effect on the antitumor immunity cycle has been discussed. Along with this, several agonists of the cGAS-STING pathway were introduced with their potential as immunotherapeutic drugs. Then, the basic biological functions of Mn²⁺ have been illustrated, focusing on its critical roles in the cGAS-STING pathway activation. Next, we systematically reviewed the Mn²⁺-based strategies for tumor immunotherapy, which can be classified by the methods based on Mn²⁺ alone or Mn²⁺ combined with other therapeutic modalities. We finally speculated the future perspectives of the field and provided rational suggestions to develop better Mn²⁺-based therapeutics.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"35 1","pages":"19-43"},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992997/pdf/cjcr-35-1-19.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9455316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management guidelines for preventing exposure to antineoplastics.","authors":"Wei Liu,&nbsp;Ziyang Wu,&nbsp;Tong Sun,&nbsp;Shuyao Liang,&nbsp;Jun Zhu,&nbsp;Suodi Zhai,&nbsp;Division Of Therapeutic Drug Monitoring Of Chinese Pharmacological Society,&nbsp;Hospital Pharmacy Professional Committee Of Chinese Pharmaceutical Association,&nbsp;Oncology Society Of Chinese Medical Association,&nbsp;Nursing Branch Of China International Exchange And Promotive Association For Medical And Healthcare,&nbsp;Division Of Drug-Induced Diseases Of Chinese Pharmacology Society","doi":"10.21147/j.issn.1000-9604.2023.01.01","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2023.01.01","url":null,"abstract":"","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"35 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992999/pdf/cjcr-35-1-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9455310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment.","authors":"Nan Chen,&nbsp;Jaffer A Ajani,&nbsp;Aiwen Wu","doi":"10.21147/j.issn.1000-9604.2023.01.05","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2023.01.05","url":null,"abstract":"<p><p>Cancers derived from the gastrointestinal (GI) tract are often treated with radical surgery to achieve a cure. However, recent advances in the management of GI cancers involve the use of a combination of neoadjuvant radiation and chemotherapy followed by surgical intervention to achieve improved local control and cure. Interestingly, a small proportion of patients with highly sensitive tumors achieved a pathological complete response (pCR) (no residual tumor cells in the resected specimen) to neoadjuvant chemoradiation therapy (nCRT). The desire for organ preservation and avoidance of surgical morbidity brings the idea of a nonoperative management (NOM) strategy. Because of the different nature of tumor biology, GI cancers present diverse responses to nCRT, ranging from high sensitivity (anal cancer) to low sensitivity (gastric/esophageal cancer). There is an increasing attention to NOM of localized GI cancers; however, without the use of biomarkers/imaging parameters to select such patients, NOM will remain a challenge. Therefore, this review intends to summarize some of the recent updates from the aspect of current nCRT regimens, criteria for patient selection and active surveillance schedules. We also hope to review significant sequelae of radical surgery and the complications of nCRT to clarify the directions for optimization of nCRT and NOM for oncologic outcomes and quality of life.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"35 1","pages":"44-57"},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992995/pdf/cjcr-35-1-44.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9455315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraperitoneal chemotherapy for gastric cancer: A contemporary perspective.","authors":"So Hyun Kang,&nbsp;Hyung-Ho Kim","doi":"10.21147/j.issn.1000-9604.2023.01.03","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2023.01.03","url":null,"abstract":"","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"35 1","pages":"15-18"},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992996/pdf/cjcr-35-1-15.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9455311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TNFR2 is a potent prognostic biomarker for post-transplant lung metastasis in patients with hepatocellular carcinoma.","authors":"Huigang Li,&nbsp;Zuyuan Lin,&nbsp;Jianyong Zhuo,&nbsp;Modan Yang,&nbsp;Wei Shen,&nbsp;Zhihang Hu,&nbsp;Yichen Ding,&nbsp;Hao Chen,&nbsp;Chiyu He,&nbsp;Xinyu Yang,&nbsp;Siyi Dong,&nbsp;Xuyong Wei,&nbsp;Beicheng Sun,&nbsp;Shusen Zheng,&nbsp;Ren Lang,&nbsp;Di Lu,&nbsp;Xiao Xu","doi":"10.21147/j.issn.1000-9604.2023.01.07","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2023.01.07","url":null,"abstract":"<p><strong>Objective: </strong>Lung metastasis is a common and fatal complication of liver transplantation for hepatocellular carcinoma (HCC). The precise prediction of post-transplant lung metastasis in the early phase is of great value.</p><p><strong>Methods: </strong>The mRNA profiles of primary and paired lung metastatic lesions were analyzed to determine key signaling pathways. We enrolled 241 HCC patients who underwent liver transplantation from three centers. Tissue microarrays were used to evaluate the prognostic capacity of tumor necrosis factor (TNF), tumor necrosis factor receptor 1 (TNFR1), and TNFR2, particularly for post-transplant lung metastasis.</p><p><strong>Results: </strong>Comparison of primary and lung metastatic lesions revealed that the TNF-dependent signaling pathway was related to lung metastasis of HCC. The expression of TNF was degraded in comparison to that in para-tumor tissues (P<0.001). The expression of key receptors in the TNF-dependent signaling pathway, TNFR1 and TNFR2, was higher in HCC tissues than in para-tumor tissues (P<0.001). TNF and TNFR1 showed no relationship with patients' outcomes, whereas elevated TNFR2 in tumor tissue was significantly associated with worse overall survival (OS) and increased recurrence risk (5-year OS rate: 31.9% <i>vs.</i> 62.5%, P<0.001). Notably, elevated TNFR2 levels were also associated with an increased risk of post-transplant lung metastasis (hazard ratio: 1.146; P<0.001). Cox regression analysis revealed that TNFR2, Hangzhou criteria, age, and hepatitis B surface antigen were independent risk factors for post-transplant lung metastasis, and a novel nomogram was established accordingly. The nomogram achieved excellent prognostic efficiency (area under time-dependent receiver operating characteristic =0.755, concordance-index =0.779) and was superior to conventional models, such as the Milan criteria.</p><p><strong>Conclusions: </strong>TNFR2 is a potent prognostic biomarker for predicting post-transplant lung metastasis in patients with HCC. A nomogram incorporating TNFR2 deserves to be a helpful prognostic tool in liver transplantation for HCC.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"35 1","pages":"66-80"},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992998/pdf/cjcr-35-1-66.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9455313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}